The Oviduct and Serous Cancer Risk Assessment

Abstract

The proposal was designed to address three issues. First could we identify stem cells fromthe fallopian tube, including from patients with high grade serous cancer (HGSC). Second,could we link the molecular abnormalities in cancer associated stem cells and validate themin pathologic material, specifically in what we feel are stem cell outgrowths or SCOUTs andthird could we identify molecular alterations that would place the oviduct or the patient atrisk for HGSC. In essence we wished to drill down to the cell of origin and link it to cancerrisk, identifying an assay that could predict the presence of cancer by analyzing lowergenital tract fluids or other samples. All of these aims have been addressed and our studieshave reinforced the likelihood that novel pathways to ovarian cancer exist, but evidencepoints to more than one mechanism and site of origin.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2016
Accession Number
AD1034527

Entities

People

  • Christopher P Crum

Organizations

  • Brigham and Women's Hospital

Tags

DTIC Thesaurus Topics

  • Cancer
  • Carcinoma
  • Cell Physiological Processes
  • Cells
  • Genetics
  • Health Services
  • Lymphocytes
  • Medical Personnel
  • Neoplasms
  • Oncology
  • Stem Cells

Readers

  • Oncology
  • Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.

Technology Areas

  • Biotechnology